Flinders University of South Australia, College of Science and Engineering, Bedford Park, SA, 5042, Australia.
The Queen Elizabeth Hospital, Infectious Diseases Unit, Woodville, SA, 5011, Australia.
Future Microbiol. 2021 Feb;16(3):135-142. doi: 10.2217/fmb-2020-0163. Epub 2021 Feb 4.
The ability of influenza A virus to evolve, coupled with increasing antimicrobial resistance, could trigger an influenza pandemic with great morbidity and mortality. Much of the 1918 influenza pandemic mortality was likely due to bacterial coinfection, including pneumonia. resists many antibiotics. The lack of new antibiotics suggests alternative antimicrobials, such as bacteriophages, are needed. Potential delivery routes for bacteriophage therapy (BT) include inhalation and intravenous injection. BT has recently been used successfully in compassionate access pulmonary infection cases. Phage lysins, enzymes that hydrolyze bacterial cell walls and which are bactericidal, are efficacious in animal pneumonia models. Clinical trials will be needed to determine whether BT can ameliorate disease in influenza and coinfection.
甲型流感病毒的进化能力，加上日益增加的抗微生物药物耐药性，可能引发具有高发病率和死亡率的流感大流行。1918 年流感大流行的大部分死亡可能是由于细菌合并感染，包括肺炎。对许多抗生素具有耐药性。缺乏新的抗生素表明需要使用替代的抗菌药物，例如噬菌体。噬菌体治疗（BT）的潜在给药途径包括吸入和静脉注射。BT 最近在同情准入肺部感染病例中成功使用。噬菌体裂解酶是一种水解细菌细胞壁的酶，具有杀菌作用，在动物肺炎模型中有效。需要进行临床试验来确定 BT 是否可以改善流感和合并感染的疾病。
